Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sheaff

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletionPeter W Szlosarek, Astero Klabatsa, Arben Pallaska, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|December 26, 2025
Intensive Surveillance and Aggressive Multimodal Treatment for Liver Metastases From Uveal MelanomaHemant M Kocher, Akil Gani, Ziya O Belibagli, et al.
The Journal of Pathology|December 23, 2011
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesotheliomaSara Busacca, Michael Sheaff, Kenneth Arthur, et al.
Plos One|June 14, 2013
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaSara Busacca, Alex D Chacko, Astero Klabatsa, et al.
JTO Clinical and Research Reports|September 30, 2021
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance MechanismsPeter W Szlosarek, Melissa M Phillips, Iuliia Pavlyk, et al.
Kidney International|April 19, 2013
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptorSina M Coldewey, Areeg I Khan, Amar Kapoor, et al.
Journal of Cutaneous Pathology|July 8, 2026
Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With ImmunosuppressionXiang Li Tan, Pooja Patel, Jeva Cernova, et al.
Pharmacological Reports : PR|May 17, 2023
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa M Phillips, Iuliia Pavlyk, Michael Allen, et al.
Pharmacological Reports : PR|April 3, 2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa M Phillips, Iuliia Pavlyk, Michael Allen, et al.
Eclinicalmedicine|June 16, 2022
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trialDean A Fennell, Catharine Porter, Jason Lester, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletionPeter W Szlosarek, Astero Klabatsa, Arben Pallaska, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|December 26, 2025
Intensive Surveillance and Aggressive Multimodal Treatment for Liver Metastases From Uveal MelanomaHemant M Kocher, Akil Gani, Ziya O Belibagli, et al.
The Journal of Pathology|December 23, 2011
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesotheliomaSara Busacca, Michael Sheaff, Kenneth Arthur, et al.
Plos One|June 14, 2013
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaSara Busacca, Alex D Chacko, Astero Klabatsa, et al.
JTO Clinical and Research Reports|September 30, 2021
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance MechanismsPeter W Szlosarek, Melissa M Phillips, Iuliia Pavlyk, et al.
Kidney International|April 19, 2013
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptorSina M Coldewey, Areeg I Khan, Amar Kapoor, et al.
Journal of Cutaneous Pathology|July 8, 2026
Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With ImmunosuppressionXiang Li Tan, Pooja Patel, Jeva Cernova, et al.
Pharmacological Reports : PR|May 17, 2023
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa M Phillips, Iuliia Pavlyk, Michael Allen, et al.
Pharmacological Reports : PR|April 3, 2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaMelissa M Phillips, Iuliia Pavlyk, Michael Allen, et al.
Eclinicalmedicine|June 16, 2022
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trialDean A Fennell, Catharine Porter, Jason Lester, et al.
Pageof 7